Outsmarting the world's most resistant pathogens.
Fedora creates novel antibiotics targeting multidrug-resistant bacteria.
Advancing antibiotic innovation since 2011.
Fedora has stepped up to tackle antimicrobial resistance, one of the world's most urgent health challenges, as identified by the World Health Organization (WHO).
A team with four decades of antibiotic discovery experience.
Fedora Pharmaceuticals Inc. is a Canadian biotechnology company dedicated to discovering and developing antibacterial therapies to combat the growing global threat of antimicrobial resistance. The first Canadian antibiotic to reach the world was tazobactam, invented by the late Dr. Ronald Micetich; the second was nacubactam, discovered by Fedora under the leadership of Christopher Micetich, cementing the Micetich family's extraordinary record of translating science into life-saving medicines. Both men have been inducted into the BioAlberta BioIndustry Hall of Fame, and each has received an Alberta ASTech Award in recognition of their achievements in scientific innovation, entrepreneurship, and advancing biotechnology.
In Canada's history, only two home-discovered antibiotics have ever reached the global market. Fedora's team discovered both.
Antimicrobial resistance is outpacing our medicines.
AMR is one of the top ten global public health threats. As bacteria evolve to resist the antibiotics modern medicine depends on, the world needs new ones. That is the problem Fedora exists to solve.
A deep portfolio against drug-resistant infection.
One market-ready asset, one preclinical candidate, and earlier-stage hits behind them.
A team that has brought antibiotics to market.
Fedora's scientists have developed anti-infectives now in clinical use.
The latest from Fedora.
In April 2026, Fedora presented its current lead, FPI-2119, in Munich: eight posters and two talks on its activity against resistant Gram-negative infections.
FPI-2119 takes center stage at ESCMID Global 2026
Eight posters and two talks on how FPI-2119 kills antibiotic-resistant bacteria.
Read more → Apr 19, 2026Presentations highlight safety & potent activity of FPI-2119
Activity data against Gram-negative community and hospital-acquired infections, across eight posters.
Read more → Apr 9, 2026Fedora to showcase its antibiotic candidate at ESCMID 2026
Preclinical findings on FPI-2119, presented in Munich.
Read more →Partner with us to preserve the power of antibiotics for future generations.
Fedora seeks partnerships and licensing agreements with industry, academia, and governments to move the pipeline forward.
Start a conversation →
